Ftse Mib
33.986,90
1,06%
DAX
18.175,21
1,01%
S&P 500
5.180,74
1,03%
NASDAQ
16.349,25
1,19%
Bitcoin
63.734,68
0,90%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. USOTC Revive Therapeutics Ltd (QB) (RVVTF) Revive Therapeutics Ltd (QB) (RVVTF) Notizie

RVVTF

Revive Therapeutics (QB) (RVVTF)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:USOTC:RVVTF
DataOraFonteTitoloSimboloCompagnia
18/04/202216:26InvestorsHub NewsWireRevive Therapeutics Announces Publication of Research Data with Bucillamine in COVID-19USOTC:RVVTFRevive Therapeutics Ltd (QB)
12/04/202214:00InvestorsHub NewsWireRevive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19USOTC:RVVTFRevive Therapeutics Ltd (QB)
24/02/202214:35InvestorsHub NewsWireHAVN Life Secures Purchase Order for Controlled Substance Sale to Revive Therapeutics Ltd. for Use in Clinical ResearchUSOTC:RVVTFRevive Therapeutics Ltd (QB)
16/02/202214:03InvestorsHub NewsWireRevive Therapeutics Receives FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver TransplantationUSOTC:RVVTFRevive Therapeutics Ltd (QB)
17/01/202215:13InvestorsHub NewsWireRevive Therapeutics Provides Update of Psilocybin Pharmaceutical ProgramsUSOTC:RVVTFRevive Therapeutics Ltd (QB)
07/01/202214:05InvestorsHub NewsWireRevive Therapeutics Clarifies Status of Its Phase 3 Clinical Trial for Bucillamine in COVID-19USOTC:RVVTFRevive Therapeutics Ltd (QB)
16/11/202114:00InvestorsHub NewsWireRevive Therapeutics Announces Published Research Results on Bucillamine as Potential Inhibitor of SARS-CoV-2 Infection Delta VariantUSOTC:RVVTFRevive Therapeutics Ltd (QB)
22/09/202113:30InvestorsHub NewsWireRevive Therapeutics Included in AdvisorShares® Newly Launched Psychedelics ETFUSOTC:RVVTFRevive Therapeutics Ltd (QB)
18/08/202112:00InvestorsHub NewsWireRevive Therapeutics Signs Exclusive Worldwide License Agreement For Medicinal Mushroom Ganoderma Lucidum To Treat CancerUSOTC:RVVTFRevive Therapeutics Ltd (QB)
12/08/202115:56InvestorsHub NewsWireRevive Confirms No Material Undisclosed InformationUSOTC:RVVTFRevive Therapeutics Ltd (QB)
10/08/202114:52InvestorsHub NewsWireRevive Therapeutics Provides Update on Psychedelics Clinical Product PipelineUSOTC:RVVTFRevive Therapeutics Ltd (QB)
15/07/202120:47InvestorsHub NewsWireRevive Therapeutics Provides Update on FDA Phase 3 Clinical Trialfor Bucillamine in COVID-19USOTC:RVVTFRevive Therapeutics Ltd (QB)
28/06/202114:00InvestorsHub NewsWireRevive Therapeutics Approved to Trade on the OTCQB MarketUSOTC:RVVTFRevive Therapeutics Ltd (QB)
17/06/202114:59InvestorsHub NewsWireRevive Collaborates With University of Health Sciences Antigua To Pioneer Clinical Research of PsychedelicsUSOTC:RVVTFRevive Therapeutics Ltd (QB)
08/06/202115:12InvestorsHub NewsWireRevive Therapeutics Partners with Supriya to Pursue EUA for Bucillamine to Treat COVID in IndiaUSOTC:RVVTFRevive Therapeutics Ltd (QB)
17/05/202115:48InvestorsHub NewsWireRevive Therapeutics Enters into Feasibility Agreement with LTS Lohmann to Develop Oral Psilocybin Thin Film StripUSOTC:RVVTFRevive Therapeutics Ltd (QB)
03/05/202115:32InvestorsHub NewsWireRevive Therapeutics Enters Into Research Agreement with UCSF For Bucillamine As Potential Treatment For Severe COVID-19USOTC:RVVTFRevive Therapeutics Ltd (QB)
27/04/202115:51InvestorsHub NewsWireRevive Therapeutics Files For FDA Orphan Drug Designation for Psilocybin in Traumatic Brain InjuryUSOTC:RVVTFRevive Therapeutics Ltd (QB)
22/04/202114:26InvestorsHub NewsWireRevive Therapeutics Announces Successful Research Results for Oral Thin Film Psilocybin and Filing of U.S. Provisional ....contUSOTC:RVVTFRevive Therapeutics Ltd (QB)
24/03/202114:15InvestorsHub NewsWireRevive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19USOTC:RVVTFRevive Therapeutics Ltd (QB)
19/03/202112:56InvestorsHub NewsWireRevive Therapeutics Announces Successful Research Results for Psilocybin to Treat Traumatic Brain Injury and Filing of ...ContUSOTC:RVVTFRevive Therapeutics Ltd (QB)
26/02/202115:01InvestorsHub NewsWireRevive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion...ContUSOTC:RVVTFRevive Therapeutics Ltd (QB)
17/02/202115:53InvestorsHub NewsWireRevive Therapeutics Acquires Unique Psilocybin AssetsUSOTC:RVVTFRevive Therapeutics Ltd (QB)
11/02/202114:05InvestorsHub NewsWireRevive Therapeutics Provides Update on Cannabinoid Pharmaceuticals ProgramUSOTC:RVVTFRevive Therapeutics Ltd (QB)
27/01/202114:13InvestorsHub NewsWireRevive Therapeutics in Phase 3 clinical trial for COVID-19 treatmentUSOTC:RVVTFRevive Therapeutics Ltd (QB)
18/01/202115:51InvestorsHub NewsWireHow Combat Sports Are Researching Micro-Dosing Psychedelics To Treat Brain InjuriesUSOTC:RVVTFRevive Therapeutics Ltd (QB)
14/01/202114:30InvestorsHub NewsWireRevive Therapeutics Announces Research Collaboration with North Carolina State UniversityUSOTC:RVVTFRevive Therapeutics Ltd (QB)
31/12/202014:30InvestorsHub NewsWireDr. John Fahy Joins Revive Therapeutics as Scientific and Clinical Advisor for COVID-19 FDA Phase 3 StudyUSOTC:RVVTFRevive Therapeutics Ltd (QB)
23/12/202015:57InvestorsHub NewsWireRevive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for BucillamineUSOTC:RVVTFRevive Therapeutics Ltd (QB)
22/12/202017:05InvestorsHub NewsWireRevive Therapeutics Announces LOI to Acquire PharmaTher's Psilocybin ProgramUSOTC:RVVTFRevive Therapeutics Ltd (QB)
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:USOTC:RVVTF

La tua Cronologia

BIT
ISP
Intesa Sanpaolo
BIT
UCG
Unicredit
BIT
ENEL
Enel
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
STLAM
Stellantis NV
BIT
RACE
Ferrari NV
BIT
AMP
Amplifon
BIT
ENI
Eni
BIT
LDO
Leonardo
BIT
STMMI
ST Microelectronics
BIT
TEN
Tenaris
BIT
BPE
Bper Banca
BIT
BAMI
Banco BPM
BIT
SPM
Saipem
BIT
TIT
Telecom Italia
BIT
TRN
Terna Trasmissione Elett...
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network